Skip to main content
Equibles
SLS logo

SLS · SELLAS Life Sciences Group, Inc.

Track SLS — free

Use SLS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SLS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.21 -2.00 (-13.15%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 11, 2026

The latest filing states the doubt was alleviated.

“In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements”
View the 10-Q filed Aug 11, 2026
Market Cap
$2.77B
Shares
201.95M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.21 Open$14.77 Day$13.15–14.79 52W close$1.39–15.46 Avg vol 30d6.8M Short int56.4M · 27.9% float · 10.4d Short vol75% Last earningsMay 27, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 11

Up next

Next earnings call
May 26, 2027 Est · unconfirmed · in 39 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.39
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +103%
above
Price vs 50-day avg +7%
above
RSI (14) 52
neutral
MACD trend Positive
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +32%
trailing
6-month return +122%
trailing
YTD return +250%
this year
Relative strength +108%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+24% holders QoQ · +67 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
27.91% of float · ▲ +2.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
204 holders — near 3-yr high, broad support
Squeeze score 85
high risk · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth +50%
Y/Y
Free cash flow $-28.4M
Balance sheet $8.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 105%
annualized · 1-yr
Max drawdown −36%
past year
ATR 9.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+103% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+24% holders QoQ · +67 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
27.91% of float · ▲ +2.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
204 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $13 · 84% Range high $15
vs 200-day avg +103% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLS
SELLAS Life Sciences Group, Inc.
this stock
$2.77B +250.4% -100.0% — 27.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
204
% held
51.2%
Net QoQ
+33.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
114
View
Short & Settlement
Short Interest Rising
Shares short
56.4M
Days to cover
10.4d
Change
+1.4M sh
View
Short Volume
Short vol %
75%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
6.6K
Value
$67.5K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
50.0%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-26.9M
EPS diluted
$-0.25
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
13
View
Exempt Offerings
Offering
$18.4M
Filed
Mar 29, 2024
View
Earnings & Events
Earnings Calls
Last call
May 27, 2026
View

Performance

5D 20D 120D MTD YTD
SLS -14.6% +32.0% +121.6% +32.0% +250.4%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -15.0% +29.0% +108.2% +29.0% +237.6%
Key facts CIK 1390478 CUSIP 81642T209 13F (30d) 165 filings 163 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)